Modern Therapeutic Approaches to the Treatment of Alcoholic Hepatitis
Treatment of alcoholic hepatitis is critical to improve survival and prevent progression to cirrhosis and liver failure. Traditional treatments, such as alcohol abstinence and symptomatic drug therapy, remain the cornerstones of treatment. However, in recent years, new drugs have emerged that have shown promise in improving outcomes in patients with alcoholic hepatitis. The purpose of this review is to present the most relevant non-drug, drug-based approaches in the treatment of this group of patients, as well as address the issue of the need for early liver transplantation. The objectives of the work included collecting modern scientific data; discussion of the specifics of each treatment method, possible limitations in the context of use in this group of patients, main advantages for patients with alcoholic hepatitis; analysis of research results that highlight the importance of the drugs used in routine practice depending on the severity of the disease. The results of the work emphasize the continued need to use non-drug methods and, based on the results of using validated scales, prescribe individual drug therapy, as well as the need for further research to optimize results in this group of patients.
Usanova A.A., Kuzma F., Novikova E.K., Sergutova N.P. 2024. Modern Therapeutic Approaches to the Treatment of Alcoholic Hepatitis. Challenges in Modern Medicine, 47(2): 158–170 (in Russian). DOI: 10.52575/2687-0940-2024-47-2-158-170
While nobody left any comments to this publication.
You can be first.
Allen S.L., Quinlan J.I., Dhaliwal A., Armstrong M.J., Elsharkawy A.M., Greig C.A., Lord J.M., Lavery G.G., Breen L. 2020. Sarcopenia in Chronic Liver Disease: Mechanisms and Countermeasures. American Journal of Physiology. Gastrointestinal and Liver Physiology. 320(3): 241–257. https://doi.org/10.1152/ajpgi.00373.2020
Arab J.P., Roblero J.P., Altamirano J., Bessone F., Chaves Araujo R., Higuera-De la Tijera F., Restrepo J.C., Torre A., Urzua A., Simonetto D.A., Abraldes J.G., Méndez-Sánchez N., Contreras F., Lucey M.R., Shah V.H., Cortez-Pinto H., Bataller R. 2019. Alcohol-Related Liver Disease: Clinical Practice Guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of Hepatology. 18(3): 518–535. https://doi.org/10.1016/j.aohep.2019.04.005
Arab J.P., Díaz L.A., Baeza N., Idalsoaga F., Fuentes-López E., Arnold J., Ramírez C.A., Morales-Arraez D., Ventura-Cots M., Alvarado-Tapias E., Zhang W., Clark V., Simonetto D., Ahn J.C., Buryska S., Mehta T.I., Stefanescu H., Horhat A., Bumbu A., Dunn W., Bataller R. 2021. Identification of Optimal Therapeutic Window for Steroid Use in Severe Alcohol-Associated Hepatitis: A Worldwide Study. Journal of Hepatology. 75(5): 1026–1033. https://doi.org/10.1016/j.jhep.2021.06.019
Baig M., Walayat S., Dhillon S., Puli S. 2020. Efficacy of Granulocyte Colony Stimulating Factor in Severe Alcoholic Hepatitis: A Systematic Review and Meta-Analysis. Cureus. 12(9): 10474. https://doi.org/10.7759/cureus.10474
Bischoff S.C., Bernal W., Dasarathy S., Merli M., Plank L.D., Schütz T., Plauth M. 2020. ESPEN Practical Guideline: Clinical Nutrition in Liver Disease. Clinical Nutrition (Edinburgh, Scotland). 39(12): 3533–3562. https://doi.org/10.1016/j.clnu.2020.09.001
Clemente-Sánchez A., Oliveira-Mello A., Bataller R. 2021. Moderate Alcoholic Hepatitis. Clinics in Liver Disease. 25(3): 537–555. https://doi.org/10.1016/j.cld.2021.03.001
Dingwall K.M., Delima J.F., Binks P., Batey R., Bowden S.C. 2022. What is the Optimum Thiamine Dose to Treat or Prevent Wernicke's Encephalopathy or Wernicke-Korsakoff Syndrome? Results of a Randomized Controlled Trial. Alcoholism, Clinical and Experimental Research. 46(6): 1133–1147. https://doi.org/10.1111/acer.14843
Dominguez M., Rincón D., Abraldes J.G., Miquel R., Colmenero J., Bellot P., García-Pagán J.C., Fernández R., Moreno M., Bañares R., Arroyo V., Caballería J., Ginès P., Bataller R. 2008. A New Scoring System for Prognostic Stratification of Patients with Alcoholic Hepatitis. The American Journal of Gastroenterology. 103(11): 2747–2756. https://doi.org/10.1111/j.1572-0241.2008.02104.x
Eslamian G., Ardehali S.H., Baghestani A.R., Vahdat Shariatpanahi Z. 2019. Effects of Early Enteral Bovine Colostrum Supplementation on Intestinal Permeability in Critically Ill Patients: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrition (Burbank, Los Angeles County, Calif.). 60: 106–111. https://doi.org/10.1016/j.nut.2018.10.013
Frenette C.T., Morelli G., Shiffman M.L., Frederick R.T., Rubin R.A., Fallon M.B., Cheng J.T., Cave M., Khaderi S.A., Massoud O., Pyrsopoulos N., Park J.S., Robinson J.M., Yamashita M., Spada A.P., Chan J.L., Hagerty D.T. 2019. Emricasan Improves Liver Function in Patients with Cirrhosis and High Model for End-Stage Liver Disease Scores Compared with Placebo. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association. 17(4): 774–783. https://doi.org/10.1016/j.cgh.2018.06.012
Galvin R., Bråthen G., Ivashynka A., Hillbom M., Tanasescu R., Leone M.A., 2010. EFNS Guidelines for Diagnosis, Therapy and Prevention of Wernicke Encephalopathy. European Journal of Neurology. 17(12): 1408–1418. https://doi.org/10.1111/j.1468-1331.2010.03153.x
Gao B. 2015. Interplay of Interleukin-22 and its Binding Protein in Controlling Liver Scarring. Hepatology (Baltimore, Md.). 61(4): 1121–1123. https://doi.org/10.1002/hep.27688
Gao B. Bataller R. 2011. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology. 141(5): 1572–1585. https://doi.org/10.1053/j.gastro.2011.09.002
Hammad A., Kaido T., Aliyev V., Mandato C., Uemoto S. 2017. Nutritional Therapy in Liver Transplantation. Nutrients. 9(10): 1126. https://doi.org/10.3390/nu9101126
Hartmann P., Hochrath K., Horvath A., Chen P., Seebauer C.T., Llorente C., Wang L., Alnouti Y., Fouts D.E., Stärkel P., Loomba R., Coulter S., Liddle C., Yu R.T., Ling L., Rossi S.J., DePaoli A.M., Downes M., Evans R.M., Brenner D.A., Schnabl B. 2018. Modulation of the Intestinal Bile Acid/Farnesoid X Receptor/Fibroblast Growth Factor 15 Axis Improves Alcoholic Liver Disease in Mice. Hepatology (Baltimore, Md.). 67(6): 2150–2166. https://doi.org/10.1002/hep.29676
Hassanein T., McClain C.J., Vatsalya V., Stein L.L., Flamm S.L., Martin P., Cave M.C., Mitchell M. Jr., Barton B., Nagy L., Szabo G., McCullough A., Dasarathy S., Shah J., Blevins C., Scott D., Krebs W., Brown J.E., Lin W. 2024. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. The American Journal of Gastroenterology. 119(1): 107–115. https://doi.org/10.14309/ajg.0000000000002275
Hassanein T., Stein L.L., Flamm S.L., Martin P., Cave M.C., Blevins C., Scott D., Krebs W., Lin W. 2019. Safety and Efficacy of DUR-928: a Potential New Therapy for Acute Alcoholic Hepatitis. Hepatology. 70: 1483A-1484A.
Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. 2018. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology (Baltimore, Md.). 67(1): 358–380. https://doi.org/10.1002/hep.29086.
Hendrikx T., Duan Y., Wang Y., Oh J.H., Alexander L.M., Huang W., Stärkel P., Ho S.B., Gao B., Fiehn O., Emond P., Sokol H., van Pijkeren J.P., Schnabl B. 2019. Bacteria Engineered to Produce IL-22 in Intestine Induce Expression of REG3G to Reduce Ethanol-Induced Liver Disease in Mice. Gut. 68(8): 1504–1515. https://doi.org/10.1136/gutjnl-2018-317232
Jepsen P., Younossi Z.M. 2021. The Global Burden of Cirrhosis: A Review of Disability-Adjusted Life-Years Lost and Unmet Needs. Journal of Hepatology. 75(1): 3–13. https://doi.org/10.1016/j.jhep.2020.11.042
Louvet A., Trabut J.B., Moreno C., Moirand R., Aubin H.J., Ntandja Wandji L.C., Nourredine M., Ningarhari M., Ganne-Carrié N., Pageaux G.P., Bailly F., Boursier J., Daeppen J.B., Luquiens A., Nguyen-Khac E., Anty R., Orban T., Donnadieu-Rigole H., Mallat, A., Bureau C., for the Groupe Collaboratif AFEF-SFA Maladie du foie liée à l'alcool 2022. Management of Alcohol-Related Liver Disease: the French Association for the Study of the Liver and the French Alcohol Society Clinical Guidelines. Liver International : Official Journal of the International Association for the Study of the Liver. 42(6): 1330–1343. https://doi.org/10.1111/liv.15221
Mathurin P., Deng Q.G., Keshavarzian A., Choudhary S., Holmes E.W., Tsukamoto H. 2000. Exacerbation of Alcoholic Liver Injury by Enteral Endotoxin in Rats. Hepatology (Baltimore, Md.). 32(5): 1008–1017. https://doi.org/10.1053/jhep.2000.19621
Mayr U., Pfau J., Lukas M., Bauer U., Herner A., Rasch, S., Schmid, R.M., Huber W., Lahmer T.,
Batres-Baires G. 2020. NUTRIC and Modified NUTRIC are Accurate Predictors of Outcome in End-Stage Liver Disease: A Validation in Critically ill Patients with Liver Cirrhosis. Nutrients. 12(7): 2134. https://doi.org/10.3390/nu12072134
McClain C.J., Rios C.D., Condon S., Marsano L.S. 2021. Malnutrition and Alcohol-Associated Hepatitis. Clinics in Liver Disease. 25(3): 557–570. https://doi.org/10.1016/j.cld.2021.03.002
Mendenhall C., Roselle G.A., Gartside P., Moritz T. 1995. Relationship of Protein Calorie Malnutrition to Alcoholic Liver Disease: a Reexamination of Data from Two Veterans Administration Cooperative Studies. Alcoholism, Clinical and Experimental Research. 19(3): 635–641. https://doi.org/10.1111/j.1530-0277.1995.tb01560.x
Meza V., Arnold J., Díaz L.A., Ayala Valverde M., Idalsoaga F., Ayares G., Devuni D., Arab J.P. 2022. Alcohol Consumption: Medical Implications, the Liver and Beyond. Alcohol and Alcoholism (Oxford, Oxfordshire). 57(3): 283–291. https://doi.org/10.1093/alcalc/agac013
Mishra A.K., Shasthry S.M., Vashishtha C. 2022. GCSF Increases the Steroid Responsiveness and 90 Day Survival in Severe Alcoholic Hepatitis Patients: A Randomised Control Trial. Hepatology. 76: 150.
Morales-Arráez D., Ventura-Cots M., Altamirano J., Abraldes J.G., Cruz-Lemini M., Thursz M.R., Atkinson S.R., Sarin S.K., Kim W., Chavez-Araujo R., Higuera-de la Tijera M.F., Singal A.K., Shah V.H., Kamath P.S., Duarte-Rojo A., Charles E.A., Vargas V., Jager M., Rautou P.E., Rincon D., Bataller R. 2022. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. The American journal of gastroenterology. 117(2): 301–310. https://doi.org/10.14309/ajg.0000000000001596
Nevens F., Andreone P., Mazzella G., Strasser S.I., Bowlus C., Invernizzi P., Drenth J.P., Pockros P.J., Regula J., Beuers U., Trauner M., Jones D.E., Floreani A., Hohenester S., Luketic V., Shiffman M., van Erpecum K.J., Vargas V., Vincent C., Hirschfield G.M., POISE Study Group. 2016. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine. 375(7), 631–643. https://doi.org/10.1056/nejmoa1509840
Periyalwar P., Dasarathy S. 2012. Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical Responses. Clinics in Liver Disease. 16(1): 95–131. https://doi.org/10.1016/j.cld.2011.12.009
Seitz H.K., Bataller R., Cortez-Pinto H., Gao B., Gual A., Lackner C., Mathurin P., Muelle, S., Szabo G., Tsukamoto H. 2018. Alcoholic Liver Disease. Nature Reviews. Disease Primers. 4(1): 16. https://doi.org/10.1038/s41572-018-0014-7
Singal A.K., Shah V.H. 2016. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis. Seminars in Liver Disease. 36(1): 56–68. https://doi.org/10.1055/s-0036-1571297
Singal A.K., Mathurin P. 2021. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review. JAMA. 326(2), 165–176. https://doi.org/10.1001/jama.2021.7683
Subramaniyan V., Chakravarthi S., Jegasothy R., Seng W.Y., Fuloria N. K., Fuloria S., Hazarika I., Das A. 2021. Alcohol-Associated Liver Disease: A Review on its Pathophysiology, Diagnosis and Drug Therapy. Toxicology Reports. 8: 376–385. https://doi.org/10.1016/j.toxrep.2021.02.010
Swart G.R., Zillikens M.C., van Vuure J.K., van den Berg J.W. 1989. Effect of a Late Evening Meal on Nitrogen Balance in Patients with Cirrhosis of the Liver. BMJ (Clinical Research Ed.). 299(6709): 1202–1203. https://doi.org/10.1136/bmj.299.6709.1202
Tayek J.A., Stolz A.A., Nguyen D.V., Fleischman M.W., Donovan J.A., Alcorn J.M., Chao D.C., Asghar A., Morgan T.R. Southern California Alcoholic Hepatitis (SCAH) Consortium 2022. A Phase II, Multicenter, Open-Label, Randomized Trial of Pegfilgrastim for Patients with Alcohol-Associated Hepatitis. E. Clinical Medicine, 54: 101689. https://doi.org/10.1016/j.eclinm.2022.101689
Xiang X., Hwang S., Feng D., Shah V.H., Gao B. 2020. Interleukin-22 in Alcoholic Hepatitis and Beyond. Hepatology International. 14(5): 667–676. https://doi.org/10.1007/s12072-020-10082-6
Zhang Y., Ma J., Jing N., Zhang H., Xie Y., Liu H., Shan X., Ren J., Jin J. 2023. Bifidobacterium animalis A12 and Lactobacillus salivarius M18-6 Alleviate Alcohol Injury by keap1-Nrf2 Pathway and Thioredoxin System. Foods (Basel, Switzerland). 12(3): 439. https://doi.org/10.3390/foods12030439
The work was performed without external sources of funding.